AxoGen (NASDAQ:AXGN) Releases Quarterly Earnings Results, Meets Estimates

AxoGen (NASDAQ:AXGN) released its quarterly earnings results on Wednesday. The medical equipment provider reported $0.12 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.12, FiscalAI reports. The company had revenue of $69.73 million during the quarter, compared to analysts’ expectations of $67.10 million. AxoGen had a negative return on equity of 10.13% and a negative net margin of 13.36%.

Here are the key takeaways from AxoGen’s conference call:

• Revenue growth accelerated: Second-quarter revenue rose 23.1% year over year to $69.7 million, led by breast revenue growth of more than 50% and broad-based gains across all three target markets.
• Management raised 2026 revenue guidance to at least $279 million, representing growth of at least 24%, while maintaining expectations for positive full-year free cash flow.
• The breast business continues to expand rapidly, reaching approximately 215 active programs and 560 active surgeons; management said patient and surgeon awareness, reimbursement, and sales-force investments are supporting substantial long-term opportunity.
• Gross margin fell to 72.7% from 74.2% a year ago because breast growth increased demand for higher-cost, longer Avance grafts. Full-year 2026 gross-margin guidance was reduced to at least 73%, with pricing and manufacturing initiatives not expected to materially help this year.
• Commercial coverage for Avance reached approximately 86% of U.S. covered lives, while Aetna’s review remains ongoing; a favorable decision could lift coverage to roughly 95% of commercial lives, but management does not include material incremental benefit from pending payer decisions in its guidance.

AxoGen Price Performance

Shares of AxoGen stock traded up $0.63 on Friday, hitting $41.98. 591,576 shares of the company were exchanged, compared to its average volume of 1,120,758. The company has a quick ratio of 5.33, a current ratio of 7.10 and a debt-to-equity ratio of 0.08. The company has a 50-day moving average price of $42.10 and a 200 day moving average price of $37.33. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of -61.65 and a beta of 1.09. AxoGen has a 1-year low of $12.39 and a 1-year high of $46.95.

Insider Buying and Selling at AxoGen

In other AxoGen news, Director Kathy Johnson Weiler sold 16,344 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $44.09, for a total value of $720,606.96. Following the completion of the sale, the director directly owned 16,344 shares of the company’s stock, valued at $720,606.96. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John Johnson sold 11,050 shares of the business’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $43.26, for a total transaction of $478,023.00. Following the completion of the transaction, the director owned 11,050 shares in the company, valued at $478,023. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 29,041 shares of company stock worth $1,268,792 in the last three months. 2.44% of the stock is owned by corporate insiders.

Institutional Trading of AxoGen

Hedge funds have recently made changes to their positions in the business. Royal Bank of Canada grew its holdings in shares of AxoGen by 14.2% in the first quarter. Royal Bank of Canada now owns 38,043 shares of the medical equipment provider’s stock valued at $704,000 after purchasing an additional 4,723 shares in the last quarter. AQR Capital Management LLC grew its holdings in AxoGen by 45.3% during the 1st quarter. AQR Capital Management LLC now owns 23,917 shares of the medical equipment provider’s stock worth $442,000 after acquiring an additional 7,453 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of AxoGen by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,185 shares of the medical equipment provider’s stock valued at $466,000 after purchasing an additional 1,057 shares during the last quarter. Jones Financial Companies Lllp lifted its position in shares of AxoGen by 104,810.0% during the 1st quarter. Jones Financial Companies Lllp now owns 10,491 shares of the medical equipment provider’s stock worth $194,000 after purchasing an additional 10,481 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in AxoGen by 37.3% in the second quarter. JPMorgan Chase & Co. now owns 379,070 shares of the medical equipment provider’s stock valued at $4,113,000 after buying an additional 103,072 shares during the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

Analyst Upgrades and Downgrades

AXGN has been the subject of several research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $55.00 target price on shares of AxoGen in a research note on Wednesday. Citizens Jmp lifted their price target on shares of AxoGen from $50.00 to $55.00 and gave the company a “market outperform” rating in a research note on Thursday. HC Wainwright boosted their price target on shares of AxoGen from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday. Wells Fargo & Company upped their price objective on shares of AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Finally, Truist Financial set a $55.00 price objective on shares of AxoGen in a report on Thursday. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, AxoGen presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.